Literature DB >> 9712465

A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.

H U Meier-Kriesche1, B Kaplan, P Brannan, B D Kahan, R J Portman.   

Abstract

Neoral, the microemulsion formulation of cyclosporine (CsA), demonstrates more consistent bioavailability than the corn oil formulation Sandimmune. Because of Neoral's rapid peak and metabolism, 8-hour dosing has to be used in many pediatric and some adult patients to maintain adequate CsA peak-to-trough ratios. Although the area under the curve (AUC) is considered the best estimate of total drug exposure, it requires repeated blood sampling. Abbreviated AUC profiles yielding excellent estimates of Neoral AUC with twice daily dosing have been described, but no such abbreviated strategy exists for 8-hour dosing. One hundred fifty-two pharmacokinetic profiles in 23 patients were used to derive and prospectively test a limited two-sample strategy to predict Neoral AUCs in pediatric and adult patients on 8-hour dosing regimens of Neoral. The formula was derived from 69 full 8-hour CsA pharmacokinetic profiles in nine children who underwent renal transplantation. Stepwise forward linear and multiple-curve regression techniques assessed the relative importance of single and combination concentration time points to predict AUC. The abbreviated profiles were validated by comparing the mean prediction error for each regression equation. The abbreviated profile calculated by second (C2)- and fourth (C4)-hour levels (AUC = 129 + 1.84 x C2 + 4.39 x C4) correlated well with the full AUC (r2 = 0.96; p < 0001). Mean prediction error was -0.4% +/- 5.48%, and no values fell outside the clinically acceptable 15% prediction error limit. Prospectively applying the formula to 83 AUCs of 14 adults who underwent renal transplantation and were taking Neoral three times a day demonstrated an excellent fit (r2 = 0.93; p < 0.001), with 94% of predicted values falling inside the +/-15% limit. The authors describe the development of a clinically acceptable, limited sampling strategy to predict 8-hour Neoral AUCs in children and adults who underwent renal transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712465     DOI: 10.1097/00007691-199808000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.

Authors:  Franziska Schädeli; Hans-Peter Marti; Felix J Frey; Dominik E Uehlinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Cyclosporine A monitoring--how to account for twice and three times daily dosing.

Authors:  Samuel Fanta; Janne T Backman; Paula Seikku; Christer Holmberg; Kalle Hoppu
Journal:  Pediatr Nephrol       Date:  2005-03-17       Impact factor: 3.714

Review 3.  The impact of age on rejection in kidney transplantation.

Authors:  Johan W de Fijter
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

5.  Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Authors:  Antonia Morita I Saktiawati; Marcel Harkema; Althaf Setyawan; Yanri W Subronto; Ymkje Stienstra; Rob E Aarnoutse; Cecile Magis-Escurra; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar; Marieke G G Sturkenboom
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

6.  Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.

Authors:  Reihaneh Abolhassani-Chimeh; Onno W Akkerman; Antonia M I Saktiawati; Nieko C Punt; Mathieu S Bolhuis; Yanri W Subronto; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar; Marieke G G Sturkenboom
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

7.  Evaluation of limited sampling strategies for tacrolimus.

Authors:  Robert A M Op den Buijsch; Afke van de Plas; Leo M L Stolk; Maarten H L Christiaans; Johannes P van Hooff; Nas A Undre; Marja P van Dieijen-Visser; Otto Bekers
Journal:  Eur J Clin Pharmacol       Date:  2007-08-22       Impact factor: 2.953

8.  Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Willy Coosemans; Jacques Pirenne; Yves Vanrenterghem
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.